Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Colm O’Reilly

DPhil (graduand), MSc, MPharm, BSc, MPSI


Postdoctoral Research Assistant in Biomedical Ultrasound for Wound Therapy

Colm O’Reilly is a Postdoctoral Research Assistant at NDORMS, University of Oxford.

He received his BSc and MPharm in Pharmacy from Royal College of Surgeons in Ireland. Colm has practised as a locum pharmacist in 184 community pharmacies in the Dublin area in Ireland.

He completed his MSc in Pharmaceutics at University College London School of Pharmacy where he focused on developing novel enteric coating systems for reliable duodenal drug delivery. Colm joined Intract Pharma, a spin out founded by Prof Abdul Basit of University College London School of Pharmacy, as a formulation scientist focusing on formulation of oral biologics for inflammatory bowel disease.

Colm completed his DPhil in Molecular and Cellular Medicine at NDORMS under the supervision of Dr Dario Carugo, Dr Michael Gray, and Prof. Eleanor Stride where he investigated the feasibility of delivering large molecular weight drugs in the gastrointestinal tract using ultrasound responsive microbubbles.

As a registered pharmacist, formulation scientist, and research scientist,  he has been involved at all stages of medicines development and use: fundamental research, formulation development, manufacturing, clinical trial design, dispensing medications and counselling patients.

In his current role, under the supervision of Prof. Eleanor Stride and Dr Dario Carugo, Colm is developing an ultrasound responsive microbubble and antibiotic loaded gel for first in human clinical study for delivery of antibiotics to infected burns in collaboration with Stoke Mandeville Hospital.

His research focuses on how to safely, locally, and reversibly modulate physiological barriers to improve drug delivery.